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Summary Bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV), JM216, is the first antineoplastic platinum compound that can be
given to patients oralty. Several phase 11 clinical trials of JM216 monotherapy have already been reported. However, no information on the
potential drug interactions caused by JM216 is available. In this study, the capacity of JM216 to inhibitcytochrome P450 (CYP) in human liver
microsomes was investigated by measuring the inhibition potential (IC5 and K) on prototype reactions. Specific substrates of GYP included
testosterone (catatysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYPlAl, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1)
and (±)-bufuralol (CYP2D6). JM216 inhibited the catalytic activities of CYP isozymes. The IC5. values were between 0.31M and 1O 1M,
indicating strong and non-specific inhibitory effects of JM216. The inhibition occurred in a non-competitive manner, and the K value was 1.0
and 0.9 gm for metabolite formation of testosterone and paclitaxel respectivety. Therefore, some in vivo studies should be conducted to
determine whether or not there is a correlation between in vivo and in vitro results.
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Platinum anti-tumour agents. such as cisplatin and carboplatin.
have been widely used in combination chemotherapy for many
cancers. especially for ovarian and lung cancers (Fukuoka et al.
1991: McGuire et al. 1996). These agents available today are.
however, generally administered intravenously. The development
ofan oral platinum drug has been desired to improve the quality of
life of patients receiving cancer chemotherapy in terms of easy
administration. Bis-acetato-ammine-dichloro-cvclohexylamine-
platinum (IV). JM216. is the first oral antineoplastic platinum
agent currently under development. In preclinical studies. JM' 16
exhibited in vitro and in vivo anti-tumour efficacy comparable
with cisplatin and carboplatin. and an activity against cell lines
that were resistant to cisplatin (Kelland et al. 1993). Several phase
H clinical trials of JM216 monotherapy have already been
performed in the United States and Europe. and a phase I study has
finished in Japan (Groen et al. 1996: Fujii et al. 1997: Peereboom
et al. 1997). Further, some combination regimens of JM216 with
other anti-tumour agents. such as taxans. can be expected. but no
information on the potential dru2 interactions bet- een JM216 and
other drugs has been reported.
The metabolic pathway of the drug is complicated and has not
been well understood (Raynaud et al. 1996). However, there are
some implications that metabolism of JM216 might affect drug-
metabolizing enzymes in the liver. First. at least six metabolites
were detected in plasma samples from patients who received
JM216 (Raynaud et al. 1996). Four of them were also obtained
by in mvitro incubations with fresh human plasma. whereas the
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remaining two metabolites were detected orly in in vivo studies.
Second. according to the results oforgan distribution in mice plat-
inum accumulated to a high level in the liver and the level was
retained steadily for several days (McKeage et al. 1994).
Besides the metabolic pathway ofJM216 itself. it is important
to evaluate the effects of the drug on the metabolism of other
drugs. This study was undertaken to investigate whether JM216
would interact with drugs being metabolized by cytochrome
P450 (CYP).
MATERIALS AND METHODS
Chemicals
JM216 was kindly provided by Bristol-Myers Squibb (Kanagawa.
Japan). JM216 (200 l-m) and cisplatin (100ILm) were suspended in
water and stored at 4CC in the dark. The stability ofJM216 in water
at this concentration was tested. As a result. 98.8%c of the drug
remained unchanred after 48 h in the dark. and 95.5% after 2 h
under room light (Bristol-Myers Squibb proprietarv information).
NADFP. glucose 6-phosphate and glucose 6-phosphate dehvdrogre-
nase were obtained from Oriental Yeast (Tokvo. Japan). Cisplatin.
baccatin III. ethoxvresorufin and resorufin were purchased from
Sigma (St Louis. MO. USA). Testosterone. taxol (paclitaxel).
coumarin. 7-hvdroxvcoumarin and aniline hvdrochlonrde were
from Wako Pure Chemical Industries (Osaka. Japan): 11 B- and 6,-
hydroxvtestosterones from Steraloid (Wilton. NH. USA): p-
aminophenol hydrochloride from Tokyo Chemical Industries
(Tokyo. Japan): and (±)-bufuralol hydrochloride and l'-hydroxxbu-
furalol from Gentest (Wobum. MA. USA): (±)-propranolol
hNdrochlonde from Aldrich (Milwaukee. AXI. USA). All other
chemicals were ofthe hirhestgrade commercially available.
Part of this research was presented at the 13th Bristol-Mvers Squibb Nagova
International Cancer Treatment Symposia. Nagova. Japan. O-tober 17-18. 1997.
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Figure 1 Inhibiion of in vitro microsomal testosterone (A), paditaxel (B), 7-ethoxyresorufin (C), coumann (D), aniline (E) and (±)-bufuralol (F) metabolism.
Concentrations of platinum compounds were 0.3, 1, 3 and 10 gm for JM216 (open symbols), and 10 gm for cisplatin (closed symbols). The rate of the metabolite
formation without JM216 was 870 (HL12) and 240 (HL48) for6"hydroxylation of testosterone, 23 (HL15) and 2.8 (HL51) for O-deethylation of 7-
ethoxyresorufin, 260 (HL12) and 80 (HL48) for 7-hydroxylatin of coumann, 380 (HL12) and 410 (HL48) for p-hydroxylation of aniline and 63 (HL12) and 120
(HL48) for 1'-hydroxylation of (±)-bufuralo (pmol min-' mg- protein). Liver microsomes from human subject HL1 2 ( A), HL1 5 (T. V), HL47 (> *), HL48
(7 U) and HL51 ( .0) were used. Each plot represents the mean of duplicate determinations
Human liver microsomes
Human liver microsomes were prepared from autopsy samples
with informed consent in writing from each guardian. The use of
human liver for the study had been approved by the Institutional
Committee of Hokkaido University. Liver tissues were stored at
-800C. Microsomes were prepared as described previously
(Kamataki and Kitagawa. 1973). and were stored at -80°C until
use. Protein concentration was measured according to the method
of Lowry et al ( 1951 ).
Analytical procedures
Inhibition by JM216 of CYP in human liver microsomes was
examined by measungn their inhibition potential (IC, and K) on
prototype reactions. Specific substrates and the reactions
measured in this study included testosterone 6f-hydroxylation
(catalysed by CYP3A4) (Waxman et al. 1988). paclitaxel 6a-
hydroxylation (CYP2C8) (Cresteil et al. 1994: Rahman et al.
1994). 7-ethoxyresorufin O-deethylation (CYPlAl. CYPIA2)
(Guengerich et al. 1982). coumarin 7-hydroxylation (CYP2A6)
(Pearce et al. 1992). aniline p-hydroxylation (CYP2EI) (Ryan
et al. 1985) and (±)-bufuralol l'-hydroxylation (CYP2D6)
(Nakamura et al. 1996). Substrates were incubated alone or
together with JM216 (0.3-10 g-t) to estimate the concentration of
JM216 yielding 50% inhibition ofthe metabolism(ICio) Values of
IC, were evaluated directly from the plots. Detailed kinetic
studies were performed to determine the apparent inhibition
constant (K!). and to clarify the mechanism(s) involved in the inhi-
bition using testosterone and paclitaxel as substrates.
All reactions were initiated by addition of each substrate after a
5-min preincubation at 37°C in a shaking water bath. JM216 or
cisplatin were preincubated in the reaction mixture before
substrate addition. In studies with testosterone. pacitaxel and (±)-
bufuralol as substrates. the determinations of metabolites were
performed by the high-performance liquid chromatoraphy
(HPLC) system. The system included a Hitachi model D-7000
(Hitachi. Tokyo. Japan) equipped with an L-7100 pump. a L-7200
autosampler and a L-7400 detector. and a Capcell Pak C18 (5 gm)
4.6 x 250 mm column (Shiseido. Tokyo. Japan). Determinations
were performed in duplicate and the representative results were
shown.
The assay of testosterone 6$-hydroxylation was performed as
described by Arlotto et al (1991). A reaction mrixture consisted of
100 mtir potassium-phosphate buffer (pH 7.4). 50 -iM EDTA. an
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Figure 2 Representative Lineweaver-Burk plots of testosterone 6l-
hydroxylation by liver microsomes from a human subject HL12 (A) and the
secondary plots showing the K value of 1.0 pu (B). The concentrations of
JM216 were 0 gm (as a control, 0), 1 iu (A) and 3 gm (U). The
concentratons of testosterone were 18.8, 37.5, 75 and 150 gm. Each plot
represents the mean of duplicate determinations
NADPH generating system (0.5 m-nt NADP+. 5 inst magnesium
chloride. 5 insm glucose 6-phosphate and 1 U mll lucose-6-
phosphate dehydrogenase). a desired concentration of JM216 or
cisplatin. and 0.2- to 0.4-mg microsomes in a final volume of 1 ml.
The final testosterone concentration was 18.8-160 gm. After a 15-
nun incubation. the reaction was terminated by addition of 5 ml of
diethylether followed by addition of 1 nmol of 11 ptestosterone as
an internal standard. The sample was mixed vigorously. and the
organic phase was separated by centrifuging. After the extract was
Figure 3 Representative Lineweaver-Burk plots of paditaxel metabolism by
liver microsomes from a human subject HL12 (A) and the secondary plots
showing the K value of 0.9 gu (B). The concentrations of JM216 were 0 gm
(as a control, 0), 1 gu (A) and 3 iu (U). The concentrations of pacitaxel
were 2.5, 5, 10, 20 m. Each plot represents the mean of duplicate
determinations
evaporated to dryness bv centrifugal evaporator Hitachi CE1D
(Hitachi Koki. Tokyo. Japan). the residue was dissolved in 200 l
of a solvent used as an initial HPLC mobile phase and the solution
applied to HPLC. The mobile phase was a mixture of methanol.
water and acetonitrile at 39:60:1 (v/v. solvent A) and at 80:18:2
(vx/v. solvent B). The separation was accomplished at 40°C using a
30-min linear gradient from 98% (v/v) solvent A (0 min) to 20%
(v/v) solvent A (30 min) at a flow rate of 1 ml mmn-'. Absorbance
was monitored at 254 nm. The formation of 6-testosterone was
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calculated by the peak height of the metabolite using a standard
curve generated by the authentic standard.
Biotransformation ofpaclitaxel was determined according to the
method reported by Harris et al (1994) with minor modifications.
Incubation mixture consisted of 100 mm potassium phosphate
buffer (pH 7.4). 50gM EDTA, 0.4-1 mg ofmicrosomal protein. an
NADPH-generating system and JM216 or cisplatin in a final
volume of I ml. Each reaction was initiated by adding 10 l of a
paclitaxel solution (0.25-2.0 mM) in methanol. After 15-min incu-
bation. the reactions were eliminatedby adding 5 ml ofacetonitrile
containing 0.5 IM baccatin m as an internal standard. Tubes were
vortexed and centrifuged, and the resultant supematant was evapo-
rated to dryness. The residue was dissolved in 200 gl of 1:1
acetonitrile-water before HPLC analysis. Under the conditions
described above, baccatin ml 6a-hydroxypaclitaxel and pacitaxel
were eluted with retention times of 18.2 min, 24.5 min and
26.7 min respectively, which were similar to those reported by
Harris et al (1994). As an authentic reference standard of the
metabolite of paclitaxel was not available, we assumed that the
metabolite eluted with a retention time of24.5 min as 6a-hydrox-
ypaclitaxel and expressed the velocity ofbiotransformation as the
peak height ratio ofthe metabolite to the intemal standard.
7-Ethoxyresorufin O-deethylation and coumarin 7-hydroxyla-
tion were measured by determination of metabolites using a
Hitachi F-2000 fluorescence spectrophotometer (Hitachi, Tokyo.
Japan: Lake, 1987; Pearce et al, 1992). Aniline p-hydroxylation
was assayed colorimetrically with a Hitachi U-1000 spectropho-
tometer (Hitachi; Imai et al. 1966). The l'-hydroxylated metabo-
lite of (±)-bufuralol was determined by HPLC as reported
previously (Nakamura et al, 1996). Incubation times were 10 min
for 7-ethoxyresorufin (with a final concentration of2 PIM), 15 min
for coumarin (50gM), 15 min for aniline (4 mM) and 30 min for
(±)-bufuralol (20giM) oxidations.
RESULTS
Effects of JM216 on the 6-hydroxylation of
testosterone
Clear inhibition by JM216 of testosterone 6$-hydroxylation was
seen. At the 160gM concentration of testosterone, an IC- value
was estimated to be between 0.3 ILM and 1 JM, suggesting a
strong inhibitory effect of JM216 on CYP3A (Figure 1).
Lineweaver-Burk plots showed that the inhibition occurred in a
non-competitive manner. and the K value derived from the
secondary plots was evaluated to be 1.0 JLM (Figure 2). The
hydroxylase also seemed to be inhibited by cisplatin, but the
inhibition was rather weak. The inhibition was only 15% at
10 Jim concentration ofcisplatin (Figure 1).
Effects of JM216 on the metabolism of paclitaxel
The hydroxylation of pactitaxel was inhibited with an IC-, value
between 1 JiM and 3 gM at a paclitaxel concentration of 10 Jim
(Figure 1). Fonnation of the metabolite, possibly 6a-hydroxy-
paclitaxel, followed Michaelis-Menten kinetics as demonstrated
by linear Lineweaver-Burk plots (Figure 3). Apparent Km value
was 17 gm, which was consistent with that measured as the forma-
tion of 6a-hydroxypaclitaxel in previous reports (Cresteil et al.
1994; Harris et al, 1994). The inhibition also occurred in a non-
competitive manner with the K, value of0.9jim (Figure 3).
Oter inhibfiton studies
The activities of 7-ethoxyresorufin O-deethylase. coumarin 7-
hydroxylase. anili p-hydroxylase and (±)-bufuralol l'-hydroxyl-
ase were inhibited by JM216 as well (Figure 1). The ICfo values
were between 3 jim and 10gM for 7-ethoxyresorufin O-deethyl-
ase, between 1 pM and 3 jM for coumarin 7-hydroxylase and
aniline p-hydroxylase, and between 0.3 jM and 1 giM for (±)-bufu-
ralol l'-hydroxylase, indicating non-specific inhibitory effects of
JM216 on CYP. On the other hand, cisplatin exhibited only scant
effects on CYP activities.
DISCUSSION
Several drugs, such as SKF-525A (Buening and Franklin. 1974).
metyrapone (Testa and Jenner. 1981), cimetidine (Winzor et al.
1986) and ketoconazole (Pasanen et al, 1988), have been known to
inhibit CYP non-specifically. JM216 would be anotherexample of
a non-specific inhibitor of CYP with high inhibition potential.
Thus, more detailed mechanism(s) responsible for the inhibition
should be investigated.
Further, it remains to be examined whether phamicokinetics of
drugs being metabolized mainly by CYP would be altered by
JM216. As in vitroresults do not always translate to the in vivo situ-
ation, and as very little ornoJM216is found in the systemic circula-
tion after oral administration in human (Raynaud et al. 1996), we
cannot be sure exactly how much, ifany, ofthe compound actually
reaches the liver through the portal vein. The in vitro inhibition of
CYPby JM216 found in this study, however, agrees with the results
of combination chemotherapy involving etoposide in vivo (Rose.
1997). When etoposide was given orally to mice in combination
with JM216, the maximum tolerated dose was reduced to 25% of
that seen with etoposide alone. Although no pharmaokinetic data
were reported. it might be possible that JM216 inhibited the metab-
olism ofetoposide. a substrate ofCYP3A (Relling et al, 1994).
This report suggests that careful attention should be paid to
interactions ofdrugs metabolized mainly by CYP, including many
antineoplastic agents, when treating cancer patients with JM216.
Additionally, if the in vitro/in vivo correlations are demonstrated.
we can propose an advantageous use of JM216 as a potential
suppresser of drug metabolism in combination cancer
chemotherapy. In other words, JM216 can be used to reduce the
necessary dose for treatment of combined agents that are detoxi-
fied by CYPs, i.e. paclitaxel (CYP2C8. CYP3A4: Cresteil et al.
1994; Harris et al, 1994; Rahman et al, 1994). docetaxel
(CYP3A4; Marre et al, 1996), etoposide (CYP3A4: Relling et al,
1994) and vinca alkaloids (CYP3A4; Zhou et al, 1993). With this
kind of intervention, the inhibition of cyclosporin or etoposide
metabolismby ketoconazole has already been used intentionally to
reduce the cost of cyclosporin treatment and to improve the
bioavailability oforal etoposide (First et al, 1989; Kobayashi et al.
1996). Schwartz et al (1995) have successfully used fluconazole to
reverse the accelerated trans-retinoic acid clearance in patients
with acute promyelocytic leukaemia On the other hand. as
cyclophosphamide and ifosfamide are activated by CYP2B and
CYP3A respectively (Chang et al. 1993). combination use of
JM216 may decrease the anti-tumour effects ofthese prodrugs.
This in vitro study revealed that JM216 inhibited multiple forms
of CYP. Therefore, some in vivo studies should be conducted to
determine whetheror not there is a correlation between in vivo and
in vitro results.
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